Lung Cancer
Volume 68, Issue 1 , Pages 51-57 , April 2010

A fast and convenient new technique to detect the therapeutic target, K-ras mutant, from peripheral blood in non-small cell lung cancer patients

  • Der-An Tsao

      Affiliations

    • School of Medical and Health Science, Fooyin University, Taiwan
    • These authors contributed equally to the manuscript, and both are considered the first author.
    • ,
  • Ming-Je Yang

      Affiliations

    • Graduate Institute of Medicine, Kaohsiung Medical University Taiwan
    • These authors contributed equally to the manuscript, and both are considered the first author.
    • ,
  • Hui-Jen Chang

      Affiliations

    • School of Medical and Health Science, Fooyin University, Taiwan
    • ,
  • Li-Chen Yen

      Affiliations

    • Graduate Institute of Medicine, Kaohsiung Medical University Taiwan
    • ,
  • Hua-Hsien Chiu

      Affiliations

    • School of Environmental and Life Sciences, Fooyin University, Koahsiung, Taiwan
    • Research and Development Headquarters, Fooyin University, Koahsiung, Taiwan
    • ,
  • Er-Jung Hsueh

      Affiliations

    • Division of Oncology and Hematology, Pingtung Christian Hospital, Taiwan
    • Departments of Internal Medicine, Pingtung Christian Hospital, Taiwan
    • ,
  • Yi-Fang Chen

      Affiliations

    • Gene Target Technology Co. Ltd., Koahsiung, Taiwan
    • ,
  • Shiu-Ru Lin

      Affiliations

    • School of Medical and Health Science, Fooyin University, Taiwan
    • Department of Medical research, Fooyin University Hospital, Taiwan
    • Corresponding Author InformationCorresponding author at: Research and Development Headquarters, Fooyin University, 151 Chin-Hsueh Rd., Ta-Liao Hsiang, Kaohsiung Hsien 831, Taiwan. Tel.: +886 7 7811151x1500; fax: +886 7 7863667.

Received 28 April 2009 ,Revised 21 May 2009 ,Accepted 24 May 2009.

References 

  1. McCormick F. ras GTPase activating protein: signal transmitter and signal terminator. Cell. 1989;56:5–8
  2. Shao J, Sheng H, DuBois RN, Beauchamp RD. Oncogenic Ras-mediated cell growth arrest and apoptosis are associated with increased ubiquitin-dependent cyclin D1 degradation. J Biol Chem. 2000;275:22916–22924
  3. Kikuchi A, Williams LT. Regulation of interaction of ras p21 with RalGDS and Raf-1 by cyclic AMP-dependent protein kinase. J Biol Chem. 1996;271:588–594
  4. Gohlke H, Kiel C, Case DA. Insights into protein-protein binding by binding free energy calculation and free energy decomposition for the Ras–Raf and Ras–RalGDS complexes. J Mol Biol. 2003;330:891–913
  5. Du W, Liu A, Prendergast GC. Activation of the PI3’K-AKT pathway masks the proapoptotic effects of farnesyltransferase inhibitors. Cancer Res. 1999;59:4208–4212
  6. Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature. 2002;418:934
  7. Bos JL. The ras gene family and human carcinogenesis. Mutat Res. 1988;195:255–271
  8. Bos JL. Ras oncogenes in human cancer: a review. Cancer Res. 1989;49:4682–4689
  9. Wang JY, Hsieh JS, Chang MY, Huang TJ, Chen FM, Cheng TL, et al. Molecular detection of APC, K-ras, and p53 mutations in the serum of colorectal cancer patients as circulating biomarkers. World J Surg. 2004;28:721–726
  10. Chong IW, Chang MY, Sheu CC, Wang CY, Hwang JJ, Huang MS, et al. Detection of activated K-ras in non-small cell lung cancer by membrane array: a comparison with direct sequencing. Oncol Rep. 2007;18:17–24
  11. Hsieh JS, Lin SR, Chang MY, Chen FM, Lu CY, Huang TJ, et al. APC, K-ras, and p53 gene mutations in colorectal cancer patients: correlation to clinicopathologic features and postoperative surveillance. Am Surg. 2005;71:336–343
  12. Wang JY, Hsieh JS, Lu CY, Yu FJ, Wu JY, Chen FM, et al. The differentially mutational spectra of the APC, K-ras, and p53 genes in sporadic colorectal cancers from Taiwanese patients. Hepatogastroenterology. 2007;54:2259–2265
  13. Wang JY, Lian ST, Chen YF, Yang YC, Chen LT, Lee KT, et al. Unique K-ras mutational pattern in pancreatic adenocarcinoma from Taiwanese patients. Cancer Lett. 2002;180:153–158
  14. Lin SR, Tsai JH, Yang YC, Lee SC. Mutations of K-ras oncogene in human adrenal tumours in Taiwan. Br J Cancer. 1998;77:1060–1065
  15. Linardou H, Dahabreh IJ, Kanaloupiti D, Siannis F, Bafaloukos D, Kosmidis P, et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol. 2008;9:962–972
  16. Perez-Soler R. Erlotinib: recent clinical results and ongoing studies in non small cell lung cancer. Clin Cancer Res. 2007;13:s4589–4592
  17. Sequist LV, Bell DW, Lynch TJ, Haber DA. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol. 2007;25:587–595
  18. Sun S, Schiller JH, Spinola M, Minna JD. New molecularly targeted therapies for lung cancer. J Clin Invest. 2007;117:2740–2750
  19. Chen YF, Wang JY, Wu CH, Chen FM, Cheng TL, Lin SR. Detection of circulating cancer cells with K-ras oncogene using membrane array. Cancer Lett. 2005;229:115–122
  20. Sambrook JFE, Maniatis T. Molecular cloning: a laboratory manual. Cold Spring Harbor Laboratories Press; 1989;
  21. Maheswaran S, Sequist LV, Nagrath S, Ulkus L, Haber DA. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med. 2008;359:366–377
  22. Wang JY, Lin SR, Wu DC, Lu CY, Yu FJ, Hsieh JS, et al. Multiple molecular markers as predictors of colorectal cancer in patients with normal perioperative serum carcinoembryonic antigen levels. Clin Cancer Res. 2007;15:2406–2413
  23. Sheu CC, Yu YP, Tsai JR, Chang MY, Lin SR, Hwang JJ, et al. Development of a membrane array-based multimarker assay for detection of circulating cancer cells in patients with non-small cell lung cancer. Int J Cancer. 2006;15:1419–1426
  24. Wang JY, Hsieh JS, Chen FM, Yeh CS, Alexandersen K, Huang TJ, et al. High frequency of activated K-ras codon 15 mutant in colorectal carcinomas from Taiwanese patients. Int J Cancer. 2003;107:387–393
  25. Guerrero S, Casanova I, Farre L, Mazo A, Capella G, Mangues R. K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression. Cancer Res. 2000;60:6750–6756
  26. Giaccone G. The role of gefitinib in lung cancer treatment. Clin Cancer Res. 2004;10:4233s–4237s
  27. Giaccone G. Clinical impact of novel treatment strategies. Oncogene. 2002;21:6970–6981

PII: S0169-5002(09)00319-5

doi: 10.1016/j.lungcan.2009.05.023

Lung Cancer
Volume 68, Issue 1 , Pages 51-57 , April 2010

Article Tools

* Image Usage & Resolution